Absorption

Absorption is the first phase of pharmacokinetics, describing how a medicine travels from where it is given (mouth, muscle, skin, lungs) into the systemic circulation where it can exert its effect. The rate and extent of absorption determine how fast a medicine starts working and how much of the dose ultimately reaches the blood. For orally administered medicines, absorption depends on dissolving in gastrointestinal fluids, crossing the intestinal epithelium, and surviving first-pass metabolism in the liver before entering general circulation.

Several factors influence absorption. Physicochemical properties of the medicine - molecular size, lipid solubility, pH, and ionization state - determine how easily it crosses membranes. Patient factors matter too: gastric pH, intestinal motility, food in the stomach, blood flow at the absorption site, and concurrent medications can all speed up or slow down absorption. Medicines given intravenously bypass absorption entirely, achieving 100% bioavailability, while oral medicines may have bioavailability as low as 5% (e.g., morphine) or as high as 95% (e.g., levothyroxine on an empty stomach).

Clinically, understanding absorption explains why some medications must be taken with food (to improve absorption or reduce stomach upset), while others must be taken on an empty stomach (food slows absorption and lowers blood levels). Levothyroxine, bisphosphonates, and many fluoroquinolone antibiotics fall into this latter group. Calcium, iron, and antacids can dramatically reduce absorption of certain antibiotics by binding them in the gut - a classic chelation interaction.

A common misconception is that a higher dose always produces a proportionally higher blood level. In reality, absorption can become saturated, and certain medicines exhibit nonlinear pharmacokinetics where doubling the dose more than doubles the blood level. Another misconception is that route of administration is interchangeable. Switching from IV to oral, or from immediate-release to extended-release formulations, often requires dose adjustment because of differences in the rate and extent of absorption.

Clinicians monitor absorption indirectly through clinical response, medicine levels, and observed side effects. Patients should be counseled on whether to take their medication with food, what to avoid (grapefruit juice, dairy, antacids), and the importance of consistent timing to maintain steady blood concentrations.

Finally, the concept of bioequivalence rests on absorption profiles. Two products are considered bioequivalent when their rate (Cmax, Tmax) and extent (AUC) of absorption fall within statistically defined limits of the reference product. This is the standard by which generic medicines are approved. Absorption variability also explains why some patients require dose adjustments despite using the same brand: gut microbiome differences, prior bariatric surgery, celiac disease, and inflammatory bowel disease can all reduce absorption surface area or alter intestinal pH enough to matter clinically. Newer medicine delivery systems - liposomal preparations, gastric-retentive technologies, nanoparticle carriers - are designed specifically to optimize absorption for medicines that would otherwise have poor or erratic oral availability.